Follow-up surveillance strategies for genitourinary malignancies
- PMID: 12115377
- DOI: 10.1002/cncr.10525
Follow-up surveillance strategies for genitourinary malignancies
Abstract
Background: Genitourinary cancers account for more than 20% of all malignancies in the United States. These cancers do not usually yield rapid mortality, thereby necessitating longer-term surveillance strategies.
Methods: A review and analysis of relevant studies were performed. Follow-up strategies are proposed to reflect effective methods to detect recurrent prostate, bladder, renal, and testicular cancers. Cost analysis was performed using Medicare reimbursement rates.
Results: For genitourinary tumors, follow-up tests can be planned rationally based on detection rates and patterns. Tumor grade and stage drive follow-up strategies, along with therapeutic implications of detecting a recurrence. Symptomatic recurrences often obviate the need for radiographic tests and can minimize costs. Stage- specific plans for these four urologic malignancies are outlined specifically.
Conclusions: Not all surveillance approaches have been critically tested for follow-up of genitourinary tumors, but ample data are available to propose sound medical and economic strategies.
Copyright 2002 American Cancer Society.
Similar articles
-
The cost of bladder tumour treatment and follow-up.Scand J Urol Nephrol. 2002;36(5):344-7. doi: 10.1080/003655902320783845. Scand J Urol Nephrol. 2002. PMID: 12487738
-
Pediatric genitourinary tumors.Curr Opin Oncol. 2007 May;19(3):248-53. doi: 10.1097/CCO.0b013e3280ad43ce. Curr Opin Oncol. 2007. PMID: 17414644 Review.
-
Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis.Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S150-4. doi: 10.1016/j.ygyno.2007.07.028. Epub 2007 Sep 14. Gynecol Oncol. 2007. PMID: 17868785
-
Costs of follow-up after potentially curative treatment for extremity soft-tissue sarcoma.Int J Oncol. 2004 Aug;25(2):429-35. Int J Oncol. 2004. PMID: 15254741
-
The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis.J Gen Intern Med. 1997 May;12(5):318-31. doi: 10.1046/j.1525-1497.1997.012005318.x. J Gen Intern Med. 1997. PMID: 9159703 Free PMC article. Review.
Cited by
-
Economic burden of renal cell carcinoma: Part I--an updated review.Pharmacoeconomics. 2011 Apr;29(4):315-29. doi: 10.2165/11586100-000000000-00000. Pharmacoeconomics. 2011. PMID: 21395351 Review.
-
[PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?].Urologe A. 2005 Sep;44(9):997-1004, 1006-7. doi: 10.1007/s00120-005-0879-4. Urologe A. 2005. PMID: 16133232 Review. German.
-
Active surveillance for prostate cancer compared with immediate treatment: an economic analysis.Cancer. 2012 Jul 15;118(14):3512-8. doi: 10.1002/cncr.26688. Epub 2011 Dec 16. Cancer. 2012. PMID: 22180322 Free PMC article.
-
Staged based directed surveillance of invasive bladder cancer following radical cystectomy: valuable and effective?World J Urol. 2006 Nov;24(5):557-64. doi: 10.1007/s00345-006-0117-8. World J Urol. 2006. PMID: 17009050 Review. No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources